UNSPSC 51111906: Pegaspargase

This classification denotes a protein synthesis inhibitor with the molecular formula C1377H2208N382O442S17, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7D96IR0PPM, more generally known as pegaspargase. European Medicines Agency schedules pegaspargase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03666MIG. The term PEGASPARGASE is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 5, no. 3 1991, list 31.

UNSPSC 51111906 Pegaspargase, a Commodity code, names a specialized injectable chemotherapy drug used in acute lymphoblastic leukemia (ALL) treatment protocols. State and local governments procure this product primarily through health departments, hospital systems, and school-based health clinics that serve pediatric and adult cancer patients. The drug is a pegylated form of asparaginase, an enzyme that depletes asparagine in leukemia cells, and is typically acquired as part of broader oncology medication formularies or through specialized pharmaceutical cooperative purchasing vehicles. Issuing bodies include state health departments managing Medicaid pharmacy benefits, county hospital systems with oncology services, and municipal public health agencies serving low-income and uninsured populations.

The source material contains no recent state and local solicitations tagged to this code, making it difficult to characterize current geographic activity or representative recent procurement opportunities. The sparse activity under this Commodity code likely reflects the narrow clinical application of pegaspargase—it is a high-cost, specialty pharmaceutical with limited patient populations—and the fact that most state and local cancer treatment procurement flows through established formulary contracts, group purchasing organizations, or state Medicaid programs rather than open solicitations. Business development professionals should verify whether opportunities in pediatric oncology drugs are being tagged to a higher-tier Family code or whether institutional relationships with state pharmacy benefit managers and hospital cooperative purchasing groups drive market access more directly than posted RFPs or IFBs.